1 |
Forni D, Cagliani R, Clerici M, Sironi M. 2018. Origin and dispersal of Hepatitis E virus. Emerg. Microbes. Infect. 7: 11.
|
2 |
Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, et al. 1991. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 185: 120-131.
DOI
|
3 |
Kang S, Choi C, Choi I, Han KN, Roh SW, Choi J, et al. 2018. Hepatitis E Virus Methyltransferase Inhibits Type I Interferon Induction by Targeting RIG-I. J. Microbiol. Biotechnol. 28: 1554-1562.
|
4 |
Kang S, Myoung J. 2017. Host Innate Immunity against Hepatitis E Virus and Viral Evasion Mechanisms. J. Microbiol. Biotechnol. 27: 1727-1735.
DOI
|
5 |
Kim N, Now H, Nguyen NTH, Yoo JY. 2016. Multilayered regulations of RIG-I in the anti-viral signaling pathway. J. Microbiol. 54: 583-587.
DOI
|
6 |
Schmidt ME, Varga SM. 2017. Modulation of the host immune response by respiratory syncytial virus proteins. J. Microbiol. 55: 161-171.
DOI
|
7 |
Theofilopoulos AN, Baccala R, Beutler B, Kono DH. 2005. Type I interferons (/) in immunity and autoimmunity. Annu. Rev. Immunol. 23: 307-336.
DOI
|
8 |
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. 2015. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15: 405-414.
DOI
|
9 |
Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, et al. 2008. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82: 335-345.
DOI
|
10 |
Takeuchi OandAkira S. 2010. Pattern recognition receptors and inflammation. Cell 140: 805-820.
DOI
|
11 |
Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6: 981-988.
DOI
|
12 |
Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, et al. 2015. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347: aaa2630.
DOI
|
13 |
Seth RB, Sun L, Ea CK, Chen ZJ. 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF- and IRF 3. Cell. 122: 669-682.
DOI
|
14 |
Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, et al. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J. Virol. 76: 5532-5539.
DOI
|
15 |
Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25: 349-360.
DOI
|
16 |
Wi J, Jeong MS, Hong HJ. 2017. Construction and characterization of an Anti-Hepatitis B Virus preS1 humanized antibody that binds to the essential receptor binding site. J. Microbiol. Biotechnol. 27: 1336-1344.
DOI
|
17 |
Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. 2003. IFN- antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 17: 488-490.
DOI
|
18 |
Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 102: 2992-2997.
DOI
|
19 |
Kang SM, Won SJ, Lee GH, Lim YS, Hwang SB. 2010. Modulation of interferon signaling by hepatitis C virus non-structural 5A protein: implication of genotypic difference in interferon treatment. FEBS Lett. 584: 4069-4076.
DOI
|
20 |
Lan KH, Lan KL, Lee WP, Sheu ML, Chen MY, Lee YL, et al. 2007. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J. Hepatol. 46: 759-767.
|
21 |
Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. 2005. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad.Sci. USA 102: 17717-17722.
DOI
|
22 |
Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA, et al. 2006. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J. Virol. 80: 9226-9235.
DOI
|
23 |
Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. 1999. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285: 107-110.
DOI
|
24 |
Jilani N, Das BC, Husain SA, Baweja UK, Chattopadhya D, Gupta RK, et al. 2007. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. J. Gastroenterol. Hepatol. 22: 676-682.
DOI
|
25 |
Navaneethan U, Al Mohajer M, Shata MT. 2008. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 28: 1190-1199.
DOI
|
26 |
Krain LJ, Nelson KE, Labrique AB. 2014. Host immune status and response to hepatitis E virus infection. Clin. Microbiol. Rev. 27: 139-165.
DOI
|
27 |
Oshiumi H, Miyashita M, Matsumoto M, Seya T. 2013. A distinct role of Riplet-mediated K63-Linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog. 9: e1003533.
DOI
|
28 |
Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, et al. 2016. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. J. Viral Hepat. 23: 294-304.
DOI
|
29 |
Karpe YA, Lole KS. 2011. Deubiquitination activity associated with hepatitis E virus putative papain-like cysteine protease. J. Gen. Virol. 92: 2088-2092.
DOI
|
30 |
Nan Y, Yu Y, Ma Z, Khattar SK, Fredericksen B, Zhang YJ. 2014. Hepatitis E virus inhibits type I interferon induction by ORF1 products. J. Virol. 88: 11924-11932.
DOI
|
31 |
Choi S, Park H, Minelko M, Kim EK, Cho MR, Nam JH. 2017. Recombinant adeno-associated virus expressing truncated IK cytokine diminishes the symptoms of inflammatory arthritis. J. Microbiol. Biotechnol. 27: 1892-1895.
DOI
|
32 |
Hamid FB, Kim J, Shin CG. 2017. Characterization of prototype foamy virus infectivity in transportin 3 knockdown human 293t cell line. J. Microbiol. Biotechnol. 27: 380-387.
DOI
|
33 |
Kim MJ, Lee SY, Kim HJ, Lee JS, Joo IS, Kwak HS, et al. 2016. Development of a one-step duplex RT-PCR method for the simultaneous detection of VP3/VP1 and VP1/P2B regions of the Hepatitis A Virus. J. Microbiol. Biotechnol. 26: 1398-1403.
DOI
|
34 |
Lee JM, Cho JB, Ahn HC, Jung W, Jeong YJ. 2017. A novel chemical compound for inhibition of SARS coronavirus helicase. J. Microbiol. Biotechnol. 27: 2070-2073.
DOI
|
35 |
Jeong H, Seong BL. 2017. Exploiting virus-like particles as innovative vaccines against emerging viral infections. J. Microbiol. 55: 220-230.
DOI
|
36 |
Lee JM, Kim J, Ryu I, Woo HM, Lee TG, Jung W, et al. 2017. An aptamer-based electrochemical sensor that can distinguish influenza virus subtype H1 from H5. J Microbiol Biotechnol. 27: 2037-2043.
DOI
|
37 |
Lim S, Cha S, Jang JH, Yang D, Choe J, Seo T. 2016. Alterations in acetylation of histone H4 Lysine 8 and trimethylation of lysine 20 associated with lytic gene promoters during Kaposi's sarcoma-associated herpesvirus reactivation. J. Microbiol. Biotechnol. 27: 189-196.
|
38 |
Elkholy YS, Hegab AS, Ismail DK, Hassan RM. 2016. Evaluation of a novel commercial quaternary ammonium compound for eradication of mycobacteria, HCV and HBV in egypt. J. Microbiol. 54: 39-43.
DOI
|
39 |
Kim JH, Lee CH, Lee SW. 2016. Hepatitis C virus infection stimulates transforming growth factor- expression through upregulating miR-192. J. Microbiol. 54: 520-526.
DOI
|
40 |
Shin JS, Ku KB, Jang Y, Yoon YS, Shin D, Kwon OS, et al. 2017. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. J. Microbiol. 55: 979-983.
DOI
|